|
Cathya
I think when they refer to the amplicon it refers to the stretch of DNA that includes her2AND something else. There were some people who suspected GRB7 was the culprit and not her2 itself. GRB7 is one of the components of the OncoDx test. Another close-lying gene in the amplicon is topoII I believe from I talk I heard Dr. Slamon give in San Antonio (for some reason I think cmyc may be too, but I am quite unsure if that is so or where I read/heard it)
Her2 may not be the whole story. If you have her1 (egfr or erbb1) positive and/or her3 positive, those may also make the difference as they join with her2 to produce the same effect.
Targeted molecular diagnostics tests for EGFR and her3. I am still waiting for the publishing of the paper on what lab tests predict tykerb efficacy. Did any members of this board listen to that talk/see that poster?
If you see my other posts from today. I opine that there are several types of her2 + breast cancer. A paper given in Molde, Norway by Dr. Stepanie Jeffreys of Stanford discusssed several different types of her2+ ER+ breast cancer--still unable to find the info published.
The mystery is unfolding. I hope we can speed it up by helping loosen the restrictions on researchers regarding stem cell use, medical privacy rules, access to specimens etc...
Will get off my soap-box for now!
Lani
|